Publication | Closed Access

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

Metabolic SyndromeLipid DisorderHeterozygous Familial HypercholesterolaemiaCardiovascular DiseaseDiabetesPharmacologyLipid-modifying TherapyPharmacotherapyMedicineDyslipidemia